GALAPAGOS NV/S (NASDAQ:GLPG) had its target price raised by HC Wainwright from $150.00 to $205.00 in a research report sent to investors on Monday, Briefing.com Automated Import reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
A number of other research firms have also commented on GLPG. ValuEngine raised shares of XPO Logistics from a strong sell rating to a sell rating in a research note on Thursday, April 4th. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a research note on Wednesday, July 10th. Credit Suisse Group initiated coverage on shares of LTC Properties in a research note on Wednesday, July 10th. They issued an underperform rating and a $19.00 price objective for the company. BidaskClub lowered shares of Weyco Group from a sell rating to a strong sell rating in a research note on Saturday, July 13th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $25.00 price objective on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. GALAPAGOS NV/S has a consensus rating of Buy and an average target price of $148.10.
Shares of NASDAQ:GLPG opened at $169.88 on Monday. GALAPAGOS NV/S has a 1-year low of $85.00 and a 1-year high of $174.63. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $129.46.
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its earnings results on Friday, April 26th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.19) by $0.18. The firm had revenue of $46.47 million during the quarter, compared to analysts’ expectations of $44.92 million. GALAPAGOS NV/S had a negative net margin of 13.24% and a negative return on equity of 3.60%. As a group, sell-side analysts anticipate that GALAPAGOS NV/S will post -4.44 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in GLPG. Pinnacle Associates Ltd. purchased a new stake in GALAPAGOS NV/S in the 1st quarter worth approximately $231,000. Comerica Bank lifted its position in GALAPAGOS NV/S by 6.3% in the 4th quarter. Comerica Bank now owns 3,120 shares of the biotechnology company’s stock worth $325,000 after buying an additional 185 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new stake in GALAPAGOS NV/S in the 1st quarter worth approximately $344,000. Stevens Capital Management LP purchased a new stake in GALAPAGOS NV/S in the 1st quarter worth approximately $398,000. Finally, DekaBank Deutsche Girozentrale lifted its position in GALAPAGOS NV/S by 121.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock worth $632,000 after buying an additional 3,400 shares in the last quarter. Institutional investors own 16.32% of the company’s stock.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.